|
7th Annual Conference Of The British HIV Association [BHIVA]27 – 29 April 2001, The Hove Centre, Brighton |
[AUTHOR(S):] C Mazhude, S Jones, PJ Easterbrook, C Taylor
The Caldecot Centre, Department of Genito-Urinary Medicine, Kings’ College Hospital, London, UK
BHIVA Conf 2001 Apr 27-29;7:O25
OBJECTIVE: To determine the association of ethnic group and sex with the development of NNRTI-induced rash in a multiethnic cohort of HIV-infected patients.
METHODS: Retrospective record analysis of all patients starting nevirapine (NVP)/efavirenz (EFV) between Jan 1997 and Jan 2000. Sex, ethnic group and stage of disease were analysed as potential risk factors for the development of the rash.
RESULTS: A total of 337 records were analysed, including 285 patients on NVP and 52 on EFV. Of the 285 on NVP, 130 (46%) were white males, 93 (33%) black females, 48 (17%) black males and 9 (3%) white females. There was no significant difference in disease stage between the various ethnic groups (24% black females had prior AIDS-defining events vs. 19% of white males). Of the 285 on NVP, 21 (7%) developed a rash, and two-thirds of these discontinued as a result. Of those that developed a rash, 13 (62%) were black females, two (10%) white females, five (24%) white males and one (5%) black male. Female sex was associated with the highest incident risk of 15% (black women 14%, white women 22%) vs. 2–4% for males. Only two patients with a rash had prior AIDS-defining events. Two-thirds were on 400 mg NVP when the rash occurred. The median time to rash was 15 days (range 2–39). Three patients developed a Steven–Johnson type syndrome (two black females, one white male). Of nine developing a rash on NVP and switching to EFV, none had a recurrence. Of the 52 started on EFV, only one white male developed a rash and the drug was stopped.
CONCLUSIONS: The 7% incidence of rash in those starting NVP falls within ranges described previously. Female sex is strongly associated with a higher risk of NVP-induced rash. These data do not suggest a difference in the risk of NVP rash on the basis of black/white ethnicity.
PRESENTING AUTHOR: C Mazhude
010427
O25
Copyright © 2001 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD